| アブストラクト | BACKGROUND/AIM: The COVID-19 prophylactic vaccine for the prevention of coronavirus infection was approved in Japan on February 14, 2021. Adverse event reports for the vaccine were collected from the Japan Adverse Drug Event Relief (JADER) database, similar to those for drugs. Reported odds ratios (RORs) and proportional reporting ratios (PRRs) are commonly used in disproportionality analysis to detect safety signals. Therefore, adverse event reports from the vaccinated population may affect the detection of safety signals for the registered drugs. This study determined the impact of adverse event reports on the detection of safety signals for a COVID-19 prophylactic vaccine by analyzing the JADER database using disproportionality analysis. PATIENTS AND METHODS: We extracted data from the JADER dataset, in which the COVID-19 vaccine was reported as a suspected drug, and selected the top 10 adverse events in terms of the number of reports. We then extracted the top 30 drugs by the amount of information in the selected 10 adverse events and compared the changes in the number of signal detections with and without the COVID-19 vaccine report data. RESULTS: The total number of adverse events reported in the JADER database during the study period was 2,002,564. Of the total number of reports, 85,489 (4.3%) reported adverse events related to the COVID-19 vaccine. Of the top 30 drugs reported in the 10 selected adverse events, the ROR and PRR were found to be lower with the inclusion of COVID-19 vaccine data than without. Detection by ROR excluded 23 out of 245 drugs, and detection by PRR excluded 34 out of 204 drugs. CONCLUSION: The rapid increase in the number of adverse event reports for the COVID-19 vaccine in JADER may affect the detection of safety signals by disproportionality analysis. |
|---|
| ジャーナル名 | In vivo (Athens, Greece) |
|---|
| Pubmed追加日 | 2023/1/3 |
|---|
| 投稿者 | Yamaoka, Kenta; Fujiwara, Masaki; Uchida, Mayako; Uesawa, Yoshihiro; Shimizu, Tadashi |
|---|
| 組織名 | Department of Pharmacy, Kobe City Medical Center General Hospital, Kobe, Japan.;School of Pharmacy, Hyogo Medical University, Kobe, Japan.;Department of Education and Research Center for Pharmacy Practice, Faculty of;Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kyotanabe,;Japan.;Department of Medical Molecular Informatics, Meiji Pharmaceutical University,;Tokyo, Japan.;School of Pharmacy, Hyogo Medical University, Kobe, Japan;;shimizu-t@hyo-med.ac.jp. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/36593055/ |
|---|
